Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

BKM120+Abiraterone Acetate for Metastatic CRPC

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Dana-Farber Cancer Institute
Sponsor:
Information provided by (Responsible Party):
Glenn Bubley, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01741753
First received: December 3, 2012
Last updated: April 2, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2017
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)